# Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

> **NCT06525389** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Duke University** · enrollment: 428 (estimated)

## Conditions studied

- Talaromycosis

## Interventions

- **DRUG:** Liposomal Amphotericin B (LAmB)
- **DRUG:** Flucytosine (5FC)
- **DRUG:** Flucytosine (5FC) placebo pill
- **DRUG:** Deoxycholate Amphotericin B (DAmB)

## Key facts

- **NCT ID:** NCT06525389
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2030-07-01
- **Final completion:** 2031-07-01
- **Target enrollment:** 428 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06525389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06525389, "Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06525389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*